Trade Angion Biomedica Corp. - ANGN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.0810 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 0.4887 |
| Open* | 0.5279 |
| 1-Year Change* | -72.36% |
| Day's Range* | 0.5242 - 0.5372 |
| 52 wk Range | 0.46-2.41 |
| Average Volume (10 days) | 28.11K |
| Average Volume (3 months) | 1.42M |
| Market Cap | 14.76M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 30.11M |
| Revenue | 2.30M |
| EPS | -1.29 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Mar 28, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 22, 2023 | 0.4887 | 0.0096 | 2.00% | 0.4791 | 0.4890 | 0.4791 |
| Mar 21, 2023 | 0.4789 | 0.0248 | 5.46% | 0.4541 | 0.4791 | 0.4493 |
| Mar 20, 2023 | 0.4881 | 0.0001 | 0.02% | 0.4880 | 0.4986 | 0.4739 |
| Mar 17, 2023 | 0.4887 | -0.0490 | -9.11% | 0.5377 | 0.5378 | 0.4823 |
| Mar 16, 2023 | 0.5081 | 0.0198 | 4.05% | 0.4883 | 0.5695 | 0.4883 |
| Mar 15, 2023 | 0.4930 | -0.0542 | -9.90% | 0.5472 | 0.5671 | 0.4888 |
| Mar 14, 2023 | 0.5372 | -0.0196 | -3.52% | 0.5568 | 0.5963 | 0.5372 |
| Mar 13, 2023 | 0.5377 | -0.0240 | -4.27% | 0.5617 | 0.5621 | 0.5208 |
| Mar 10, 2023 | 0.5132 | -0.0641 | -11.10% | 0.5773 | 0.5778 | 0.5054 |
| Mar 9, 2023 | 0.5568 | -0.0604 | -9.79% | 0.6172 | 0.6256 | 0.5375 |
| Mar 8, 2023 | 0.5960 | 0.0078 | 1.33% | 0.5882 | 0.6158 | 0.5882 |
| Mar 7, 2023 | 0.6060 | -0.0094 | -1.53% | 0.6154 | 0.6155 | 0.6056 |
| Mar 6, 2023 | 0.6256 | -0.0208 | -3.22% | 0.6464 | 0.6466 | 0.6079 |
| Mar 3, 2023 | 0.6156 | 0.0290 | 4.94% | 0.5866 | 0.6258 | 0.5865 |
| Mar 2, 2023 | 0.5969 | 0.0009 | 0.15% | 0.5960 | 0.6130 | 0.5960 |
| Mar 1, 2023 | 0.5883 | -0.0370 | -5.92% | 0.6253 | 0.6256 | 0.5855 |
| Feb 28, 2023 | 0.6258 | 0.0006 | 0.10% | 0.6252 | 0.6452 | 0.6252 |
| Feb 27, 2023 | 0.6453 | 0.0001 | 0.02% | 0.6452 | 0.6454 | 0.6451 |
| Feb 24, 2023 | 0.6455 | 0.0006 | 0.09% | 0.6449 | 0.6736 | 0.6264 |
| Feb 23, 2023 | 0.6449 | -0.0001 | -0.02% | 0.6450 | 0.6454 | 0.6367 |
Angion Biomedica Corp. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total revenue | 28.312 | 2.88 | 1.487 | 4.029 |
| Revenue | 28.312 | 2.88 | 1.487 | 4.029 |
| Cost of Revenue, Total | 0.433 | 1.19 | 0.64 | 0.378 |
| Gross Profit | 27.879 | 1.69 | 0.847 | 3.651 |
| Total Operating Expense | 66.714 | 58.153 | 40.078 | 18.371 |
| Selling/General/Admin. Expenses, Total | 18.488 | 17.986 | 9.601 | 5.391 |
| Research & Development | 48.698 | 38.977 | 29.837 | 12.602 |
| Operating Income | -38.402 | -55.273 | -38.591 | -14.342 |
| Interest Income (Expense), Net Non-Operating | -2.191 | -8.249 | 0.488 | 0.401 |
| Other, Net | -13.98 | -16.527 | -2.555 | -6.084 |
| Net Income Before Taxes | -54.573 | -80.107 | -40.658 | -20.025 |
| Net Income After Taxes | -54.573 | -80.107 | -40.658 | -20.025 |
| Net Income Before Extra. Items | -54.573 | -80.107 | -40.658 | -20.025 |
| Net Income | -54.573 | -80.107 | -40.658 | -20.025 |
| Total Adjustments to Net Income | 0 | -4.98 | ||
| Income Available to Common Excl. Extra. Items | -54.573 | -80.107 | -40.658 | -25.005 |
| Income Available to Common Incl. Extra. Items | -54.573 | -80.107 | -40.658 | -25.005 |
| Diluted Net Income | -54.573 | -80.107 | -40.658 | -25.005 |
| Diluted Weighted Average Shares | 28.2448 | 14.7621 | 9.97635 | 9.97635 |
| Diluted EPS Excluding Extraordinary Items | -1.93214 | -5.42652 | -4.07544 | -2.50643 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
| Diluted Normalized EPS | -1.96418 | -5.4226 | -4.07544 | -2.50643 |
| Gain (Loss) on Sale of Assets | 0 | -0.058 | ||
| Unusual Expense (Income) | -0.905 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total revenue | 1.648 | 25.941 | 1.46 | 0.54 | 0.371 |
| Revenue | 1.648 | 25.941 | 1.46 | 0.54 | 0.371 |
| Cost of Revenue, Total | 0.433 | 0 | 0 | 0 | |
| Gross Profit | 25.508 | 1.46 | 0.54 | 0.371 | |
| Total Operating Expense | 16.133 | 11.307 | 17.218 | 17.879 | 20.31 |
| Selling/General/Admin. Expenses, Total | 4.466 | 4.206 | 3.93 | 4.34 | 6.012 |
| Research & Development | 11.667 | 6.668 | 13.288 | 14.444 | 14.298 |
| Operating Income | -14.485 | 14.634 | -15.758 | -17.339 | -19.939 |
| Interest Income (Expense), Net Non-Operating | 0.206 | -0.016 | -0.074 | 0.067 | -2.168 |
| Other, Net | 0.039 | 0.272 | 0.128 | 0.2 | -14.58 |
| Net Income Before Taxes | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
| Net Income After Taxes | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
| Net Income Before Extra. Items | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
| Net Income | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
| Income Available to Common Excl. Extra. Items | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
| Income Available to Common Incl. Extra. Items | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
| Diluted Net Income | -14.24 | 14.89 | -15.704 | -17.072 | -36.687 |
| Diluted Weighted Average Shares | 29.9592 | 29.9654 | 29.8296 | 29.6703 | 23.4438 |
| Diluted EPS Excluding Extraordinary Items | -0.47531 | 0.49691 | -0.52646 | -0.57539 | -1.56489 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.47531 | 0.49691 | -0.52646 | -0.60589 | -1.56489 |
| Unusual Expense (Income) | 0 | 0 | -0.905 | ||
| Gain (Loss) on Sale of Assets | 0 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total Current Assets | 91.247 | 42.297 | 6.106 | 25.679 |
| Cash and Short Term Investments | 88.756 | 34.607 | 5.571 | 25.512 |
| Cash & Equivalents | 88.756 | 34.607 | 5.571 | 25.512 |
| Total Receivables, Net | 0.806 | 5 | 0.44 | 0.107 |
| Prepaid Expenses | 1.031 | 0.352 | 0.095 | 0.06 |
| Total Assets | 96.513 | 47.347 | 11.886 | 26.628 |
| Property/Plant/Equipment, Total - Net | 4.437 | 4.228 | 4.781 | 0.017 |
| Property/Plant/Equipment, Total - Gross | 4.954 | 4.654 | 5.109 | 0.295 |
| Accumulated Depreciation, Total | -0.517 | -0.426 | -0.328 | -0.278 |
| Long Term Investments | 0.723 | 0.822 | 0.999 | 0.932 |
| Total Current Liabilities | 11.296 | 107.449 | 26.575 | 7.355 |
| Accounts Payable | 4.71 | 5.578 | 11.239 | 0.534 |
| Accrued Expenses | 4.113 | 7.276 | 3.694 | 2.98 |
| Notes Payable/Short Term Debt | 0 | 51.43 | 5.848 | 0 |
| Other Current Liabilities, Total | 2.415 | 43.165 | 5.794 | 3.841 |
| Total Liabilities | 15.006 | 137.796 | 30.472 | 7.717 |
| Total Long Term Debt | 0.235 | 0.635 | 0 | 0 |
| Other Liabilities, Total | 3.475 | 29.712 | 3.897 | 0.362 |
| Total Equity | 81.507 | -90.449 | -18.586 | 18.911 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | |
| Common Stock | 0.3 | 0.156 | 0.095 | 0.094 |
| Additional Paid-In Capital | 296.445 | 72.136 | 63.584 | 60.138 |
| Retained Earnings (Accumulated Deficit) | -215.135 | -160.562 | -80.455 | -39.797 |
| Treasury Stock - Common | 0 | -1.846 | -1.81 | -1.524 |
| Total Liabilities & Shareholders’ Equity | 96.513 | 47.347 | 11.886 | 26.628 |
| Total Common Shares Outstanding | 29.9591 | 15.3167 | 9.97635 | 9.97635 |
| Other Current Assets, Total | 0.654 | 2.338 | ||
| Long Term Debt | 0 | 0.635 | ||
| Other Equity, Total | -0.103 | -0.333 | ||
| Other Long Term Assets, Total | 0.106 | |||
| Current Port. of LT Debt/Capital Leases | 0.058 | |||
| Capital Lease Obligations | 0.235 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 76.239 | 91.247 | 104.393 | 119.702 | 133.498 |
| Cash and Short Term Investments | 73.002 | 88.756 | 102.736 | 117.313 | 130.456 |
| Cash & Equivalents | 73.002 | 88.756 | 102.736 | 117.313 | 130.456 |
| Total Receivables, Net | 0 | 0.806 | 0 | 0 | 0 |
| Prepaid Expenses | 0.021 | 1.031 | 1.018 | 1.761 | 2.343 |
| Other Current Assets, Total | 3.216 | 0.654 | 0.639 | 0.628 | 0.699 |
| Total Assets | 81.258 | 96.513 | 109.94 | 125.359 | 139.2 |
| Property/Plant/Equipment, Total - Net | 4.209 | 4.437 | 4.652 | 4.776 | 4.787 |
| Property/Plant/Equipment, Total - Gross | 4.758 | 4.954 | 5.137 | 5.231 | 5.219 |
| Accumulated Depreciation, Total | -0.549 | -0.517 | -0.485 | -0.455 | -0.432 |
| Long Term Investments | 0.732 | 0.723 | 0.862 | 0.843 | 0.877 |
| Other Long Term Assets, Total | 0.078 | 0.106 | 0.033 | 0.038 | 0.038 |
| Total Current Liabilities | 10.381 | 11.296 | 17.946 | 20.524 | 16.963 |
| Accounts Payable | 3.433 | 4.71 | 7.679 | 9.307 | 6.69 |
| Accrued Expenses | 6.16 | 4.113 | 6.219 | 5.522 | 4.872 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0.895 |
| Other Current Liabilities, Total | 0.728 | 2.415 | 4.048 | 5.695 | 4.506 |
| Total Liabilities | 14.056 | 15.006 | 45.426 | 48.17 | 46.757 |
| Total Long Term Debt | 0.219 | 0.235 | 0 | 0 | 0 |
| Long Term Debt | 0 | 0 | 0 | 0 | |
| Other Liabilities, Total | 3.456 | 3.475 | 27.48 | 27.646 | 29.794 |
| Total Equity | 67.202 | 81.507 | 64.514 | 77.189 | 92.443 |
| Common Stock | 0.3 | 0.3 | 0.304 | 0.303 | 0.3 |
| Additional Paid-In Capital | 296.476 | 296.445 | 298.518 | 295.636 | 292.67 |
| Retained Earnings (Accumulated Deficit) | -229.375 | -215.135 | -230.025 | -214.321 | -197.249 |
| Treasury Stock - Common | 0 | -4.21 | -4.21 | -2.991 | |
| Other Equity, Total | -0.199 | -0.103 | -0.073 | -0.219 | -0.287 |
| Total Liabilities & Shareholders’ Equity | 81.258 | 96.513 | 109.94 | 125.359 | 139.2 |
| Total Common Shares Outstanding | 29.9594 | 29.9591 | 29.9331 | 29.7976 | 29.6605 |
| Current Port. of LT Debt/Capital Leases | 0.06 | 0.058 | |||
| Capital Lease Obligations | 0.219 | 0.235 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Net income/Starting Line | -54.573 | -80.107 | -40.658 | -20.025 |
| Cash From Operating Activities | -52.643 | -22.888 | -24.589 | -8.02 |
| Cash From Operating Activities | 0.091 | 0.098 | 0.05 | 0.002 |
| Non-Cash Items | 27.809 | 31.352 | 6.269 | 9.051 |
| Cash Taxes Paid | 0 | 0 | ||
| Cash Interest Paid | 0.007 | 0 | 0 | |
| Changes in Working Capital | -25.97 | 25.769 | 9.75 | 2.952 |
| Cash From Investing Activities | -0.382 | -0.041 | -0.242 | 0 |
| Capital Expenditures | -0.382 | -0.041 | -0.242 | 0 |
| Cash From Financing Activities | 107.171 | 52.409 | 4.89 | 31.741 |
| Issuance (Retirement) of Stock, Net | -0.617 | 20.813 | -0.375 | 28.596 |
| Issuance (Retirement) of Debt, Net | 0.293 | 32.118 | 5.265 | 3.145 |
| Net Change in Cash | 54.149 | 29.036 | -19.941 | 23.721 |
| Financing Cash Flow Items | 107.495 | -0.522 | ||
| Foreign Exchange Effects | 0.003 | -0.444 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.24 | -54.573 | -69.463 | -53.759 | -36.687 |
| Cash From Operating Activities | -15.653 | -52.643 | -38.281 | -23.082 | -12.551 |
| Cash From Operating Activities | 0.032 | 0.091 | 0.059 | 0.029 | 0.006 |
| Non-Cash Items | 0.179 | 27.809 | 25.729 | 23.505 | 21.675 |
| Changes in Working Capital | -1.624 | -25.97 | 5.394 | 7.143 | 2.455 |
| Cash From Investing Activities | 0 | -0.382 | -0.346 | -0.285 | -0.041 |
| Capital Expenditures | 0 | -0.382 | -0.346 | -0.285 | -0.041 |
| Cash From Financing Activities | -0.014 | 107.171 | 106.767 | 106.068 | 108.444 |
| Financing Cash Flow Items | 0 | 107.495 | -5.52 | -5.428 | -2.797 |
| Issuance (Retirement) of Stock, Net | 0 | -0.617 | 112.287 | 111.496 | 111.241 |
| Issuance (Retirement) of Debt, Net | -0.014 | 0.293 | 0 | 0 | 0 |
| Foreign Exchange Effects | -0.087 | 0.003 | -0.011 | 0.005 | -0.003 |
| Net Change in Cash | -15.754 | 54.149 | 68.129 | 82.706 | 95.849 |
| Cash Interest Paid | 0.007 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Satterfield (Thomas A Jr) | Individual Investor | 7.2983 | 2197825 | 623278 | 2022-12-31 | LOW |
| Vifor (International), Ltd | Corporation | 6.6269 | 1995643 | 0 | 2023-03-15 | LOW |
| EISA-ABC LLC | Corporation | 5.719 | 1722237 | 0 | 2023-03-15 | LOW |
| Goldberg (Itzhak D) | Individual Investor | 5.6193 | 1692199 | 4213 | 2023-03-15 | LOW |
| Venkatesan (Jay R) | Individual Investor | 3.9765 | 1197498 | 0 | 2023-03-15 | LOW |
| BVF Partners L.P. | Hedge Fund | 3.5574 | 1071297 | 0 | 2022-12-31 | LOW |
| Nantahala Capital Management, LLC | Hedge Fund | 3.4308 | 1033145 | -32867 | 2022-12-31 | MED |
| Ganzi (Victor F.) | Individual Investor | 3.25 | 978698 | 0 | 2023-03-15 | LOW |
| CM Management, LLC | Investment Advisor | 2.4313 | 732178 | 132178 | 2022-12-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.1386 | 644035 | 675 | 2022-12-31 | LOW |
| Park West Asset Management LLC | Hedge Fund | 1.2311 | 370724 | 0 | 2022-12-31 | MED |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.5811 | 175000 | 0 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5593 | 168436 | -451 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.4041 | 121700 | -87277 | 2022-12-31 | HIGH |
| Omenn (Gilbert S) | Individual Investor | 0.2667 | 80326 | 0 | 2023-03-15 | LOW |
| Millennium Management LLC | Hedge Fund | 0.2502 | 75342 | -50261 | 2022-12-31 | HIGH |
| Raymond James & Associates, Inc. | Research Firm | 0.1992 | 60000 | 0 | 2022-12-31 | LOW |
| Birchview Capital, LP | Investment Advisor | 0.1806 | 54392 | 0 | 2022-12-31 | LOW |
| Ergoteles Capital | Hedge Fund | 0.1757 | 52913 | -25944 | 2022-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.1696 | 51069 | 1188 | 2022-12-31 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group500K+
Traders
92K+
Active clients monthly
$53M+
Monthly investing volume
$30M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Angion Biomedica Corp. Company profile
About Angion Biomedica Corp
Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other organs, such as the lungs, central nervous system (CNS) and heart. It is also evaluating ANG-3777 for indications within acute lung injury (ALI), with focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. The Company’s other programs are for the treatment of fibrotic diseases, ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Financial summary
BRIEF: For the nine months ended 30 September 2021, Angion Biomedica Corp revenues decreased 2% to $2.4M. Net loss increased 36% to $69.5M. Revenues reflect Grant revenue decrease from $2.4M to $0K. Higher net loss reflects Research and development - Balancing increase of 40% to $36.9M (expense), Other Non Operati decrease from $10K (income) to $3.6M (expense), Stock-based Compensation in R&D increase from $1.6M to $5.1M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
7-57 Wells Avenue
NEWTON
MASSACHUSETTS 02459
US
Income Statement
- Annual
- Quarterly
News
Sweatcoin price prediction: What is Sweatcoin?
Can Sweatcoin run to the front of the crypto pack?
15:19, 23 March 2023
Who owns the most bitcoin?
Want to know who owns the most bitcoin? Learn more about the biggest bitcoin whales.
14:54, 23 March 2023
Ethereum price prediction: Post-Merge ETH recovering
Can ETH continue to regain its losses after the market crash that followed The Merge?
14:26, 23 March 2023
Bitcoin price prediction 2030-2050: What might happen to BTC in the long term?
Bitcoin started 2023 with a rally, but for how long can it last and what’s the long-term outlook?
13:52, 23 March 2023
Solana price prediction: Can SOL rebound?
Can SOL cryptocurrency continue to recover?
12:44, 23 March 2023
China Evergrande offers bond and equity swaps in debt restructuring
Adds proposal detail
15:24, 22 March 2023
Mexico inflation rate brings good news, uncertainty remains -Espinosa
Updates with additional information from interview, context
15:19, 22 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com